|
[1] KCK J,THEILMANN L,GALLE P,et al. Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus[J]. Hepatology,1996,23(3):405-413.
|
|
[2] WANG J,SHEN T,HUANG X,et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol,2016,65(4):700-710.
|
|
[3] JANSEN L,KOOTSTRA NA,van DORT KA,et al. Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues[J]. J Infect Dis,2016,213(2):224-232.
|
|
[4] LAM AM,REN S,ESPIRITU C,et al. Hepatitis B virus capsid assembly modulators,but not nucleoside analogs,inhibit the production of extracellular pregenomic RNA and spliced RNA variants[J]. Antimicrob Agents Chemother,2017,61(8):e00680-17.
|
|
[5] PRAKASH K,RYDELL GE,LARSSON SB,et al. High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles[J]. Virol J,2018,15(1):86.
|
|
[6] BAI L,ZHANG X,KOZLOWSKI M,et al. Extracellular hepatitis B virus RNAs are heterogeneous in length and circulate as capsidantibody complexes in addition to virions in chronic hepatitis B patients[J]. J Virol,2018,92(24):e00798-18.
|
|
[7] CHEN J,WU M,WANG F,et al. Hepatitis B virus spliced variants are associated with an impaired response to interferon therapy[J]. Sci Rep,2015,5:16459.
|
|
[8] KAIRAT A,BEERHEIDE W,ZHOU G,et al. Truncated hepatitis B virus RNA in human hepatocellular carcinoma:Its representation in patients with advancing age[J]. Intervirology,1999,42(4):228-237.
|
|
[9] ZHANG P,LIU F,GUO F,et al. Characterization of novel hepadnaviral RNA species accumulated in hepatoma cells treated with viral DNA polymerase inhibitors[J]. Antiviral Res,2016,131:40-48.
|
|
[10] WANG J,SHENG Q,DING Y,et al. HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient[J]. J Hepatol,2018,68(4):847-849.
|
|
[11] BUTLER EK,GERSCH J,MCNAMARA A,et al. Hepatitis B virus serum DNA and RNA levels in nucleos(t)ide analog-treated or untreated patients during chronic and acute infection[J]. Hepatology,2018,68(6):2106-2117.
|
|
[12] WANG J,YU Y,LI G,et al. Natural history of serum HBVRNA in chronic HBV infection[J]. J Viral Hepat,2018,25(9):1038-1047.
|
|
[13] van CAMPENHOUT MJH,van BMMEL F,PFEFFERKORN M,et al. Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment[J].Hepatology,2018,68(3):839-847.
|
|
[14] HUANG H,WANG J,LI W,et al. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-nave HBV-infected individuals[J]. J Clin Virol,2018,99-100:71-78.
|
|
[15] WANG J,YU Y,LI G,et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients[J]. J Hepatol,2017,pii:S0168-8278(17)32261-4.
|
|
[16] GIERSCH K,ALLWEISS L,VOLZ T,et al. Serum HBV pgRNA as a clinical marker for cccDNA activity[J]. J Hepatol,2017,66(2):460-462.
|
|
[17] LIAO H,LIU Y,LI X,et al. Monitoring of serum HBV RNA,HBcrAg,HBs Ag and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy[J]. Antivir Ther,2019,24(2):105-115.
|
|
[18] van BMMEL F,van BMMEL A,KRAUEL A,et al. Serum HBV RNA as a predictor of peginterferon alfa-2a response in patients with HBe Ag-positive chronic hepatitis B[J]. J Infect Dis,2018,218(7):1066-1074.
|
|
[19] WANG J,DU M,HUANG H,et al. Reply to:"Serum HBV pgRNA as a clinical marker for cccDNA activity":Consistent loss of serum HBV RNA might predict the"para-functional cure"of chronic hepatitis B[J]. J Hepatol,2017,66(2):462-463.
|
|
[20] HUANG YW,TAKAHASHI S,TSUGE M,et al. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy[J]. Antivir Ther,2015,20(4):369-375.
|
|
[21] van BMMEL F,BARTENS A,MYSICKOVA A,et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors[J]. Hepatology,2015,61(1):66-76.
|
|
[22] LUO H,ZHANG XX,CAO LH,et al. Serum hepatitis B virus RNA is a predictor of HBe Ag seroconversion and virological response with entecavir treatment in chronic hepatitis B patients[J]. World J Gastroenterol,2019,25(6):719-728.
|
|
[23] HATAKEYAMA T,NOGUCHI C,HIRAGA N,et al. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine[J]. Hepatology,2007,45(5):1179-1186.
|
|
[24] GANE EJ. Future anti-HBV strategies[J]. Liver Int,2017,37(Suppl 1):40-44.
|
|
[25] SORIANO V. Hot news:Hepatitis B gene therapy coming to age[J]. AIDS Rev,2018,20(2):125-127.
|
|
[26] LAM AM,ESPIRITU C,VOGEL R,et al. Preclinical characterization of NVR 3-778,a first-in-class capsid assembly modulator against hepatitis B virus[J]. Antimicrob Agents Chemother,2019,63(1)pii:e01734-18.
|
|
[27] YUEN MF,GANE EJ,KIM DJ,et al. Antiviral activity,safety,and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection[J]. Gastroenterology,2019,156(5):1392-1403.
|
|
[28] LAHLALI T,BERKE JM,VERGAUWEN K,et al. Novel potent capsid assembly modulators regulate multiple steps of the hepatitis B virus life cycle[J]. Antimicrob Agents Chemother,2018,62(10). pii:e00835-18.
|
|
[29] SARIN SK,KUMAR M,LAU GK,et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B:A 2015update[J]. Hepatol Int,2016,10(1):1-98.
|
|
[30] European Association for the Study of the Liver. EASL 2017Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol,2017,67(2):370-398.
|
|
[31] TERRAULT NA,LOK ASF,MCMAHON BJ,et al. Update on prevention,diagnosis,and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J]. Hepatology,2018,67(4):1560-1599.
|
|
[32] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention andtreatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
|
|
[33] TSUGE M,MURAKAMI E,IMAMURA M,et al. Serum HBV RNA and HBe Ag are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients[J]. J Gastroenterol,2013,48(10):1188-1204.
|
|
[34] WANG J,CHEN X,WU Y,et al. Serum HBV RNA is a potential predictor of hepatitis B surface antigen reversion[J]. Hepatol Commun,2018,2(10):1168-1171.
|
|
[35] LU F,WANG J,CHEN X,et al. Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs[J]. Front Med,2017,11(4):502-508.
|
|
[36] LU FM,WANG J,CHEN XM,et al. The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B[J]. Chin J Hepatol,2017,25(2):105-110.(in Chinese)鲁凤民,王杰,陈香梅,等.乙型肝炎病毒RNA病毒样颗粒的发现及其对抗病毒治疗临床实践的潜在影响[J].中华肝脏病杂志,2017,25(2):105-110.
|
|
[37] LU FM,DOU XG,ZHANG WH,et al. Clinical significance of serum HBV RNA measurement in chronic hepatitis B patients[J]. J Clin Hepatol,2018,34(5):934-938.(in Chinese)鲁凤民,窦晓光,张文宏,等.慢性乙型肝炎患者血清HBV RNA检测的临床意义[J].临床肝胆病杂志,2018,34(5):934-938.
|
DownLoad: